Back

JPP · Lens · A Mini Review: Mucormycosis in Coronavirus Disease-19, Host-Iron Assimilation, and Probiotics as Novel Therapy

PDF

Article · Volume 12, Issue 3 · pp. 120–124

A Mini Review: Mucormycosis in Coronavirus Disease-19, Host-Iron Assimilation, and Probiotics as Novel Therapy

Ankit Bhardwaj1, Vandana Roy2, Indu Priyadarshini1

  1. 1Department of Pharmacology, ABVIMS and Dr. RML Hospital, New Delhi, India.
  2. 2Department of Pharmacology, MAMC and LNJP Hospital, New Delhi, India.

Abstract

Mucormycosis is an acute fungal infection with 90% of cases in the form of rhino-orbito-cerebellar. It is an aggressive and life-threatening fungal infection causing 50% mortality in people with coronavirus disease 2019 (COVID‑19). In COVID‑infected patients due to, diabetic ketoacidosis, epithelial damage, ciliary dysfunction, dysfunctional phagocytic mechanism, and immunosuppression, there is impaired chemotaxis and defective intracellular killing leads to fungal spores to invade, germinate and penetrate in surrounding tissues. The use of broad‑spectrum antibiotics disrupts the normal microbiomes and increases the probability of growth of Rhizopus spp. Commercially available probiotics such as Lactobacillus, Bifidobacterium, Enterococcus, Streptococcus, and Saccharomyces when administered in adequate quantities form siderophores which induces iron stress in fungus and inhibits spore germination.

Keywords: Coronavirus disease-19; iron chelators; mucormycosis; probiotics

The full text of this article is available as a PDF. Open the PDF.